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Background. Strict deﬁnition of invasive aspergillosis (IA) cases is required to allow precise conclusions about
the efﬁcacy of antifungal therapy. The Global Comparative Aspergillus Study (GCAS) compared voriconazole to
amphotericin B (AmB) deoxycholate for the primary therapy of IA. Because predeﬁned deﬁnitions used for this
trial were substantially different from the consensus deﬁnitions proposed by the European Organization for Research
and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 episodes of the GCAS according to
the later deﬁnitions.
Methods. The objectives were to assess the impact of the current deﬁnitions on the classiﬁcation of the episodes
and to provide comparative efﬁcacy for probable/proven and possible IA in patients treated with either voriconazole
or AmB. In addition to original data, we integrated the results of baseline galactomannan serum levels obtained from
249 (65.7%) frozen samples. The original response assessment was accepted unchanged.
Results. Recategorization allowed 59 proven, 178 probable, and 106 possible IA cases to be identiﬁed. A higher
favorable 12-week response rate was obtained with voriconazole (54.7%) than with AmB (29.9%) (P < .0001). Sur-
vival was higher for voriconazole for mycologically documented (probable/proven) IA (70.2%) than with AmB
(54.9%) (P = .010). Higher response rates were obtained in possible IA treated with voriconazole vs AmB with
the same magnitude of difference (26.2%; 95% conﬁdence interval [CI], 7.2%–45.3%) as in mycologically document-
ed episodes (24.3%; 95% CI, 11.9%–36.7%), suggesting that possible cases are true IA.
Conclusions. Recategorization resulted in a better identiﬁcation of the episodes and conﬁrmed the higher efﬁ-
cacy of voriconazole over AmB deoxycholate in mycologically documented IA.
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preemptive therapy.
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Invasive aspergillosis (IA) is an opportunistic fungal infection
occurring primarily in patients with prolonged neutropenia
and in those receiving high-dose chemotherapy or immunosup-
pressants. Although signiﬁcant advances have been made in the
diagnosis of this disease, it remains difﬁcult to obtain a myco-
logical conﬁrmation of infection [1].
The ﬁrst international consensus deﬁnitions of invasive fun-
gal diseases were published by the European Organization for
Research and Treatment of Cancer/Mycoses Study Group
(EORTC/MSG) in 2002 [2], which deﬁned 3 levels of certainty
of IA proven, probable, or possible disease. The deﬁnitions were
subsequently revised in 2008 to restrict the deﬁnitions of possi-
ble invasive diseases to the more likely cases based on more spe-
ciﬁc pulmonary abnormalities [3].
Neither of the 2 major clinical trials conducted in IA during
the last decade—the Global Comparative Aspergillus Study
(GCAS), which compared voriconazole to amphotericin B
(AmB) followed by other licensed antifungal therapy, and a
comparison of liposomal AmB 3 mg/kg daily to 10 mg/kg
daily—was able to apply these deﬁnitions strictly [4, 5].
Hence, patients with host factors and nodular lung lesions sur-
rounded by a halo sign in the absence of mycological conﬁrma-
tion were classiﬁed as probable IA. According to current revised
EORTC/MSG deﬁnitions, these cases cannot be considered as
probable IA disease as there is no mycological support, but
can only be deemed possible cases. Such possible cases repre-
sented a signiﬁcant proportion of the total number of cases in
these studies, so this may have had an impact on their conclu-
sions. As these form the basis of the current guidelines for treat-
ing IA, we recategorized all the cases of aspergillosis enrolled
into the GCAS and applied the 2008 EORTC/MSG deﬁnitions
for invasive fungal diseases.
PATIENTS AND METHODS
Objectives
The primary objective was to assess the impact of the revised
EORTC/MSG deﬁnitions on the classiﬁcation of IA compared
to those that were originally used in the GCAS. Secondary ob-
jectives were to provide comparative efﬁcacy data in mycologi-
cally documented (probable or proven) and possible IA in
patients treated with either voriconazole or AmB.
Patients
The GCAS was a prospective, randomized, multicenter trial
conducted between July 1997 and October 2000 comparing vor-
iconazole (6 mg/kg intravenously twice daily on day 1 followed
by 4 mg/kg intravenously twice daily for ≥7 days, followed by
200 mg twice daily orally), with AmB deoxycholate (1.0–1.5
mg/kg intravenously once daily) as ﬁrst-line therapy in patients
with IA followed by other licensed antifungal therapy [4]. The
protocol had been approved by the institutional review boards,
and written informed consent had been obtained from all pa-
tients or their legal guardians.
Original Procedure and Recategorization
Originally, a data review committee of 4 teams of 2 clinicians
and 1 radiologist blinded to study drug assignment conﬁrmed
the diagnosis of probable or deﬁnite IA for each patient and re-
jected from modiﬁed intent-to-treat (mITT) population those
cases that did not meet the predeﬁned criteria [4]. These criteria
differed in several points from those subsequently deﬁned by
the EORTC/MSG in 2002 and revised in 2008 (Table 1) [2,
3]. Five physicians (R. H., T. F. P., O. M., M. A. S., J. M.), belong-
ing to either the MSG or the EORTC Infectious Diseases Group,
recategorized all the episodes according to the 2008 revised
criteria.
Data available included demographics, underlying condition
and predisposing factors, clinical and detailed radiological
signs, and mycological data. In addition, we included the results
of galactomannan serum levels that had been determined by
a central laboratory from frozen samples after the original anal-
ysis had been done. Overall, 249 patients had a serum
Table 1. Major Differences Between Original Classiﬁcation in
the Global Comparative Aspergillosis Study and Recategorization
According to 2008 European Organization for Research and
Treatment of Cancer/Mycoses Study Group Criteria
Criteria
Original
Classification in
GCAS
Recategorization
According to 2008
Criteria
Host factors + nodule
with a halo or an air
crescent sign, no
positive mycologya
Probable invasive
aspergillosisa
Possible invasive
aspergillosis
Host factors + nodule
(without halo) or dense
well-circumscribed
lesion(s), no positive
mycologya
Uncertain (not
eligible)
Possible invasive
aspergillosis
Positive microscopy or
culture in
bronchoalveolar lavage
fluid in neutropenic
patients or allogeneic
HSCTb
Definite invasive
aspergillosis
Probable invasive
aspergillosis
Positive Aspergillus
galactomannan in
serumc
Results not
available at
time of primary
analysis
Results available
and used for the
recategorization
Abbreviations: GCAS, Global Comparative Aspergillosis Study; HSCT,
hematopoietic stem cell transplant.
a In the absence of other documented etiology.
b With presence of appropriate radiological signs.
c Positive Aspergillus galactomannan in bronchoalveolar lavage fluid is also
accepted as mycological criteria in 2008 criteria, but no sample has been
tested in patients included in this study.
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galactomannan collected at baseline. The experts were blinded
to the treatment groups, to the response and survival, and to ad-
verse events. All discrepancies by >1 expert were reviewed in a
second turn to reach a consensus.
Deﬁnition of Aspergillosis Cases for Recategorization
All enrolled patients into GCAS were recategorized according to
the revised EORTC/MSG deﬁnitions [3]. In summary, proven
IAwas deﬁned by a positive microscopy, culture, or histopathol-
ogy from a usually sterile ﬂuid or tissue; probable IA was de-
ﬁned by host factors, presence of typical clinical and/or
radiological signs, and positive microscopy, culture from spu-
tum, or bronchoalveolar lavage (BAL) ﬂuid or by single or mul-
tiple positive galactomannan test in serum with a cutoff index of
≥0.5 (Platelia Aspergillus, Bio-Rad); possible infection was de-
ﬁned by presence of host factors and of typical radiological signs
but without any mycological support. BAL ﬂuid was not tested
for galactomannan. Episodes were classiﬁed according to the
data available at baseline before starting therapy. Cases that
did not meet the criteria for proven, probable, or possible IA
were classiﬁed as either not aspergillosis when an alternative eti-
ology had been established or uncertain if there was no
explanation.
Original categorization included 3 categories: deﬁnite, prob-
able, and uncertain or not aspergillosis. Recategorization in-
cluded 4 categories: proven, probable, possible, and uncertain
or not aspergillosis.
Response Assessment
The original response assessment was accepted unchanged: fa-
vorable responses were deﬁned by partial (≥50% decrease in
size of the lesion and clinical improvement) or complete re-
sponses, and unfavorable responses were deﬁned by stable dis-
ease, treatment failure, or indeterminate responses [4]. Post hoc
efﬁcacy analysis was performed in all patients with IA and also
separately on possible cases (equivalent to preemptive therapy)
and on the mycologically documented (probable and proven)
cases (equivalent to targeted therapy).
The original assessment of response at the end of randomized
therapy and survival at 12 weeks in all 379 patients enrolled in
the trial was accepted unchanged. The 12-week response was as-
sessed in 27 cases from the uncertain or not aspergillosis group
that had not been included in the original analysis as they had
been upgraded to eligible cases after recategorization. Eighteen
of these patients died before week 12 and were classiﬁed as fail-
ing treatment, and 9 were alive. For these 9 cases, the last avail-
able efﬁcacy assessment was extended to week 12: 8 were
treatment failures, indeterminate, or stable and were all classi-
ﬁed as unfavorable response at week 12 (3 in voriconazole group
and 5 in AmB group), 1 was a partial response, and was accept-
ed as a favorable response at 12 weeks (AmB group).
Statistics
All eligible cases were assessed for response at end of randomized
therapy and at week 12 and for the secondary outcome of 12-
week survival. Treatment groups were compared by the differenc-
es in their baseline characteristics and in response rates by using,
where appropriate, 2-sided unpaired t test, Fisher exact test, or χ2
test and, when appropriate, the corresponding 2-sided 95% con-
ﬁdence interval (CI). Survival curves were compared by the log-
rank test. P values < .05 were considered signiﬁcant.
RESULTS
Agreement Between the Experts
There was concordance in the recategorization in 312 of the 379
(82.3%) cases. A single expert disagreement occurred in 52
(13.7%) cases. These cases were reviewed by the coordinator
for consistency, and a decision in favor of the majority was
made. In 15 (4.0%) cases, a disagreement by 2 members led
to a second round of review and a discussion to obtain a ﬁnal
agreement. Initial classiﬁcation remained unchanged in 181
(47.8%) cases. A change in category was made in 198 (52.2%)
cases.
Recategorization of the Cases
Of the 379 patients, 102 patients had been originally excluded
from the mITT analysis because they did not meet the protocol-
speciﬁed criteria for a diagnosis of deﬁnite or probable IA (Fig-
ure 1). The most common cause for exclusion was absence of a
halo sign around a nodular lesion. Of these 102 cases, 42 cases
now met the 2008 EORTC/MSG criteria for possible IA (be-
cause of a nodule without halo or a focal dense lesion at com-
puted tomography [CT]), 28 now met the criteria for probable
IA (positive galactomannan in serum or positive microscopy or
culture in a respiratory sample and a nodule without halo or a
focal dense lesion at CT), 3 were upgraded to proven IA (2 pa-
tients receiving steroids and 1 nonneutropenic patient with my-
eloma and a positive culture from a cerebral abscess, lung
biopsy, and vitrectomy), and 29 remained classiﬁed as uncertain
or not aspergillosis (Figure 1).
Of the 169 probable IA cases in the original study, 101 re-
mained probable (host criteria, typical imaging, and mycologi-
cal conﬁrmation by positive culture from a relevant site in 39
patients; microscopy or histopathology from a relevant site
without positive culture in 29 patients; and positive serum gal-
actomannan only in 33 patients), 64 were downgraded from
probable to possible IA (host criteria, nodule with a halo or
air-crescent sign, and no mycological conﬁrmation), and 4
were downgraded to uncertain (insufﬁcient host factors in 2 pa-
tients, positive culture from a wound swab without histopathol-
ogy demonstrating tissue invasion in 1 patient, and insufﬁcient
radiological signs in 1 patient) (Figure 1).
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Of the 108 cases originally classiﬁed as deﬁnite IA, 56 re-
mained proven (positive culture from a tissue biopsy or a sterile
ﬂuid in 7 patients, positive histology or microscopy from a tissue
or a sterile ﬂuid in 49 patients), 49 were downgraded to probable
IA (positive culture from BAL ﬂuid or bronchial aspirate or
brushing in 48 patients, positive sinus aspirate in 1 patient),
and 3 were downgraded to uncertain (positive culture in BAL
ﬂuid but nonconsistent or lack of radiological data) (Figure 1).
The new recategorization identiﬁed 59 proven, 178 probable,
and 106 possible IA cases and 36 uncertain or not aspergillosis.
Characteristics of the Patients With IA
The distribution of demographic characteristics and of underly-
ing conditions did not differ between voriconazole-treated and
AmB-treated patients with possible, probable, or proven IA
(Table 2). Half of the patients were neutropenic at baseline.
Response at End of Randomized Therapy
Overall, 343 cases of possible, probable, and proven IA were
identiﬁed (179 in voriconazole arm and 164 in AmB arm)
after recategorization. Favorable response at end of randomized
therapy was higher for patients treated with voriconazole than
in those given AmB (97/179 [54.2%] vs 34/164 [20.7%], respec-
tively, P < .0001; difference in treatment group: 33.5% [95% CI
of the difference: 23.2%–43.8%]; Table 3). Subgroup analysis
according to levels of certainty showed a higher favorable end
of randomized treatment response for those cases of possible
IA, and of mycologically documented (probable or proven)
IA treated with voriconazole (Table 3).
Response at Week 12
A higher favorable response at week 12 was seen for those treated
with voriconazole than for those given AmB (98/179 [54.7%] vs
49/164 [29.9%], respectively, P < .0001; difference in treatment
group: 24.9% [95% CI of the difference: 14.4%–35.4%]; Table 3).
Subgroup analysis showed a higher favorable 12-week response
rate for patients given voriconazole for possible and for mycolog-
ically documented (probable or proven) IA (Table 3).
Survival
A larger proportion of patients with possible, probable, or prov-
en IA survived to week 12 in the voriconazole group compared
with those randomized to AmB (73.7% vs 59.1%, P = .0028;
hazard ratio [HR], 0.57 [95% CI, .39–.82]; Figure 2).
Subgroup analysis showed a numerically higher survival for
patients with a possible IAwho had been treated with voricona-
zole (81.8%) compared with those given AmB (68.6%); howev-
er, the difference did not reach statistical signiﬁcance (P = .11;
HR, 0.53 [95% CI, .25–1.15]). Survival was higher for patients
given voriconazole for a mycological documented (probable or
proven) IA than for those treated with AmB (70.2% vs 54.9%,
Figure 1. Recategorization of the 379 cases. Left bar: original classiﬁca-
tion of the cases in the original Global Comparative Aspergillus Study
(GCAS). Right bar: distribution of the cases after recategorization. The num-
bers in the ﬁgure show how cases originally classiﬁed in the GCAS
[4] would be now be deﬁned according to European Organization for Re-
search and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
deﬁnitions [3].
Table 2. Main Characteristics of the 343 Patients With a
Possible, Probable, or Proven Invasive Aspergillosis After
Recategorization
Characteristics
Voriconazole
(n = 179)
Amphotericin B
(n = 164)
P
Value
Age, y, median (range) 42 (13–79) 52.5 (12–75) .20
Sex, male, No. (%) 117 (65.4) 101 (61.6) .50
Underlying condition,
No. (%)
.69
Allogeneic HSCT 41 (22.9%) 34 (20.7)
Autologous HSCT 11 (6.1) 8 (4.9)
Acute myeloblastic
leukemia
64 (35.8) 63 (38.4)
Acute lymphoblastic
leukemia
15 (8.4) 12 (7.3)
Other hematologic
malignancy
21 (11.7) 25 (15.2)
Solid organ cancer 2 (1.1) 0
Solid organ transplant 11 (6.1) 6 (3.7)
Other nonmalignant
diseasea
14 (7.8) 16 (9.8)
Neutrophils <500/µL 90 (50.3) 81 (49.4) .91
Abbreviation: HSCT, hematopoietic stem cell transplant.
a Mostly high-dose steroid-treated or human immunodeficiency virus–positive
patients.
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respectively, P = .010; HR, 0.58 [95% CI, .38–.88]). Separation of
probable and proven cases showed persistence of a signiﬁcant
difference in favor of voriconazole in probable IA but not in
proven IA (Table 4). Twelve-week survival was higher for the
41 allogeneic hematopoietic stem cell transplant recipients
treated with voriconazole than for the 34 who had been given
AmB (68.3% vs 35.3%, respectively, P = .0017; HR, 0.35 [95%
CI, .17–.66]).
Irrespective of the treatment arm, univariate analysis showed
improved 12-week survival for possible IA compared with prob-
able and proven IA (75.5% vs 62.9%, respectively, P = .021; HR,
0.60 [95% CI, .43–.93]). There was no difference in 12-week sur-
vival between probable and proven IA (62.9% vs 62.7%, respec-
tively, P = .91; HR, 0.97 [95% CI, .60–1.57]) nor between patients
who were neutropenic at baseline and those who were not (67.3%
vs 66.3%, respectively, P = .97; HR, 0.99 [95% CI, .69–1.44]).
Table 3. Response Rate at End of Randomized Therapy and at Week 12 According to Treatment Group and Level of Certainty
Response
Possible Invasive
Aspergillosis
Probable and Proven Invasive
Aspergillosis
All Episodes of Invasive
Aspergillosis
VOR (n = 55) AmB (n = 51) VOR (n = 124) AmB (n = 113) VOR (n = 179) AmB (n = 164)
Response at end of randomized therapy
Favorable responsea, No. (%) 34 (61.8) 12 (23.5) 63 (50.8) 22 (19.5) 97 (54.2) 34 (20.7)
Unfavorable responseb, No. (%) 21 (38.2) 39 (76.5) 61 (49.2) 91 (80.5) 82 (45.8) 130 (79.3)
Difference in response rate, % (95% CI) 38.3 (19.4–57.2) 31.3 (19.1–43.6) 33.5 (23.2–43.8)
P value <.0001 <.0001 <.0001
Response at week 12
Favorable responsea, No. (%) 36 (65.5) 20 (39.2) 62 (50.0) 29 (25.7) 98 (54.7) 49 (29.9)
Unfavorable responseb, No. (%) 19 (34.5) 31 (60.8) 62 (50.0) 84 (74.3) 81 (45.3) 115 (70.1)
Difference in response rate, % (95% CI) 26.2 (7.2–45.3) 24.3 (11.9–36.7) 24.9 (14.4–35.4)
P value .011 .0002 <.0001
Abbreviations: AmB, amphotericin B; CI, confidence interval; VOR, voriconazole.
a Complete or partial response.
b Stable disease, progression, or indeterminate.
Figure 2. Twelve-week survival curves according to treatment arm in all possible, probable, and proven invasive aspergillosis (IA) (A); probable and proven
IA (B ); possible IA (C ); and possible, probable, and proven IA in allogeneic hematopoietic stem cell transplant recipients (D ). Abbreviations: AmB, ampho-
tericin B; VOR, voriconazole.
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Twelve-week survival was lower for allogeneic hematopoietic
stem cell transplant recipients than for other patients (53.3% vs
70.5%, respectively, P = .007; HR, 1.72 [95% CI, 1.19–2.97]).
Impact of Recategorization on Efﬁcacy Results
Response and survival rates at week 12 are similar in results
after recategorization in all episodes as well as in subgroups of
probable and of proven IA compared with the original GCAS
results (Table 4). As groups are not independent, no formal stat-
istical comparison was performed.
DISCUSSION
Most recent clinical trials investigating efﬁcacy and safety of an-
tifungal agents in IA have applied the updated EORTC/MSG
deﬁnition criteria to establish the level of certainty of the diag-
nosis of IA, and to minimize intra- and interstudy variability in
the patient population. Two of the largest trials of the treatment
of IA to date, the GCAS and the comparative liposomal AmB
study, were conducted before these revised criteria had been elab-
orated and therefore there are signiﬁcant differences in the deﬁ-
nition of IA cases between recent and older trials [4–8]. IA
remains difﬁcult to diagnose early, as no diagnostic test has a
high sensitivity at early stage of disease [1]. Many IA cases are
suspected only because of typical risk factors and suggestive clin-
ical and radiological features but cannot be conﬁrmed with either
direct mycological tests (microscopy, culture, or histopathology)
or indirect tests such as Aspergillus galactomannan.
Not surprisingly, the recategorization of cases from the
GCAS using the 2008 EORTC/MSG criteria identiﬁed almost
50% fewer patients with proven IA. This is appropriate, as
most of the cases that were downgraded had been categorized
as proven based on a positive culture or microscopy from
BAL ﬂuid despite the fact that the lower respiratory tract can
be colonized by Aspergillus even among patients with underly-
ing hematological disorders. Up to one-quarter of cancer pa-
tients and hematopoietic stem transplant recipients have a
signiﬁcant concomitant respiratory condition (eg, bronchiolitis,
chronic obstructive pulmonary disease), and it has been sug-
gested that this could predispose to colonization by Aspergillus
[9]. The absence of another etiology likely increases the proba-
bility of IA in these patients, but positive BAL ﬂuid is not ac-
cepted as a surrogate marker of tissue invasion. Classiﬁcation
of such episodes as a probable IA is thus appropriate.
In our series, probable IA was also deﬁned more stringently.
EORTC/MSG deﬁnitions require mycological evidence to clas-
sify a case as probable IA. The original GCAS trial, as well as the
comparative liposomal AmB trial, accepted as probable asper-
gillosis cases deﬁned by a nodule surrounded by a halo sign
in patients at high risk of fungal disease even in the absence
of mycological documentation [4, 5]. In the GCAS, 97 of 277
(35.0%) cases in the mITT population were inadequately classi-
ﬁed as probable based on the revised criteria, whereas in the
comparative liposomal AmB trial as many as 59% of the cases
were not mycologically documented. The integration of galacto-
mannan results obtained in 65.7% of the patients signiﬁcantly
increased the rate of mycological documentation. Lack of galac-
tomannan results in one-third of the patients and long storage
of the serum before galactomannan testing are limitations in
this study. Storage may be associated with a major decrease in
galactomannan index and therefore our recategorization may
still underestimate the true rate of probable cases [10].
As expected, we and others have shown that possible IA has a
much better outcome than probable or proven IA [5, 6].
Table 4. Comparison of 12-Week Favorable Response and Survival Rates in the Original Global Comparative Aspergillus Study and After
Recategorization According to Level of Certainty of Aspergillosis
Response
Possible Invasive
Aspergillosis
Probable Invasive
Aspergillosis
Proven (Definite) Invasive
Aspergillosis
All Episodes of Invasive
Aspergillosis
Original Recategorization Original Recategorization Original Recategorization Original Recategorization
Response at week 12
Voriconazole
Favorable response,
No./total (%)
NA 36/55 (65.5) 46/77 (59.7) 49/89 (55.1) 30/67 (44.8) 13/35 (37.1) 76/144 (52.8) 98/179 (54.7)
Amphotericin B
Favorable response,
No./total (%)
NA 20/51 (39.2) 34/92 (37.0) 23/89 (25.8) 8/41 (19.5) 6/24 (25.0) 42/133 (31.6) 49/164 (29.9)
Survival at week 12
Voriconazole
Survived (%) NA 81.8 75.3 73.0 67.2 62.9 70.8 73.7
Amphotericin B
Survived (%) NA 68.6 62.0 52.8 48.8 62.5 57.9 59.1
Abbreviation: NA, not applicable.
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Therefore, a very high proportion of possible cases in any given
study may result in an overly optimistic estimation of the efﬁ-
cacy of treatment. In our analysis, 12-week survival in probable
and proven IA (70.2%) was similar to that observed in the orig-
inal analysis (70.8%) in the voriconazole-treated patients. By
contrast, similar recategorization of cases in the comparative li-
posomal AmB trial showed a 12-week survival of only 58% in
the subset of patients with true probable or proven IA (3 mg/kg
arm) vs 71% for the whole population [5, 6].
It remains unclear whether possible cases truly represent IA
in patients at risk. A negative serum galactomannan test may
not be sufﬁcient to exclude the diagnosis as the sensitivity of
the test can be <70% even in neutropenic patients [11]. More-
over, the detection of galactomannan may be impaired in pa-
tients receiving prior antimold therapy, patients having
positive anti-Aspergillus antibodies, and very likely among
those with limited disease [12, 13]. The difference in response
rates and in survival between patients treated with voricona-
zole and those given AmB is of the same magnitude for pos-
sible IA as for probable and proven IA. This difference in
response and survival rates between voriconazole-treated pa-
tients and AmB-treated patients is not explained by earlier dis-
continuation of therapy for toxicity in the AmB arm [4, 14, 15].
Therefore, the signiﬁcant beneﬁt of voriconazole over AmB
treatment among patients with possible IA strongly supports
the notion that many of these patients did, indeed, actually
have IA and therefore required antifungal therapy, likely rep-
resenting true cases (albeit early disease). This likely explains
the better response than was seen for those with proven and
probable IA.
Integration of baseline serum galactomannan results and
application of the 2008 EORTC/MSG criteria resulted in
more reliable identiﬁcation of patients with probable or proven
IA, and identiﬁcation of a signiﬁcant subgroup of patients with
well-deﬁned possible IA missing from the earlier analysis. The
efﬁcacy results did not change despite this reclassiﬁcation con-
ﬁrming the superiority of voriconazole over AmB. These
results also strongly support the contention that possible IA
as deﬁned by the 2008 EORTC/MSG criteria represents an
early phase of the invasive process in many of these highly im-
munosuppressed patients. The improved survival also supports
the view that therapy be given preemptively for IA among
high-risk patients.
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